Items where Subject is "diseases & disorders > cancer > drugs and therapies > Immunotherapy"

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Authors | Item Type
Jump to: B | C | F | G | J | T
Number of items at this level: 9.

B

Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., Vonderheide, R. H., Pittet, M. J., Jain, R. K., Zou, W., Howcroft, T. K., Woodhouse, E. C., Weinberg, R. A., Krummel, M. F. (May 2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med, 24 (5). pp. 541-550. ISSN 1078-8956

C

Connell, C. M., Raby, S., Beh, I., Flint, T., Williams, E., Fearon, D. T., Jodrell, D. I., Janowitz, T. (July 2017) Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes. Ann Oncol, 28 (7). pp. 1678-1679. ISSN 0923-7534

Connell, C. M., Raby, S. E. M., Beh, I., Flint, T. R., Williams, E. H., Fearon, D. T., Jodrell, D. I., Janowitz, T. (January 2018) Cancer Immunotherapy Trials Underutilize Immune Response Monitoring. Oncologist, 23 (1). pp. 116-117. ISSN 1083-7159

F

Fearon, D. T. (March 2017) Immune-Suppressing Cellular Elements of the Tumor Microenvironment. Annual Review of Cancer Biology, 1 (1). pp. 241-255. ISSN 2472-3428

Fessas, P., Lee, H., Ikemizu, S., Janowitz, T. (April 2017) A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol, 44 (2). pp. 136-140. ISSN 0093-7754

Flint, T. R., Jones, J. O., Ferrer, M., Colucci, F., Janowitz, T. (March 2018) A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy. Semin Oncol. ISSN 0093-7754

G

Ghosh, D., Venkataramani, P., Nandi, S., Bhattacharjee, S. (January 2019) CRISPR-Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics. Cancer Cell Int, 19. p. 12. ISSN 1475-2867 (Print)1475-2867

J

Janowitz, T., Welsh, S. J., Zaki, K., Mulders, P., Eisen, T. (August 2013) Adjuvant therapy in renal cell carcinoma-past, present, and future. Semin Oncol, 40 (4). pp. 482-91. ISSN 0093-7754

T

Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T. H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., Ziv, E., Culhane, A. C., Paull, E. O., Sivakumar, I. K. A., Gentles, A. J., Malhotra, R., Farshidfar, F., Colaprico, A., Parker, J. S., Mose, L. E., Vo, N. S., Liu, J., Liu, Y., Rader, J., Dhankani, V., Reynolds, S. M., Bowlby, R., Califano, A., Cherniack, A. D., Anastassiou, D., Bedognetti, D., Rao, A., Chen, K., Krasnitz, A., Hu, H., Malta, T. M., Noushmehr, H., Pedamallu, C. S., Bullman, S., Ojesina, A. I., Lamb, A., Zhou, W., Shen, H., Choueiri, T. K., Weinstein, J. N., Guinney, J., Saltz, J., Holt, R. A., Rabkin, C. E., Lazar, A. J., Serody, J. S., Demicco, E. G., Disis, M. L., Vincent, B. G., Shmulevich, L. (April 2018) The Immune Landscape of Cancer. Immunity, 48 (4). pp. 812-830. ISSN 1074-7613

This list was generated on Tue Mar 19 04:20:34 2019 EDT.
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving